Materias dentro de su búsqueda.
Mostrando 69,321 - 69,340 Resultados de 70,973 Para Buscar '"stroke"', tiempo de consulta: 0.46s Limitar resultados
  1. 69321
    “…METHODS: We applied Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2019 analytical tools to calculate the age-standardized incidence, prevalence, DALY, and mortality rate of overall and type-specific CVDs (i.e., rheumatic heart disease, ischemic heart disease, stroke, hypertensive heart disease, non-rheumatic valvular heart disease, cardiomyopathy and myocarditis, atrial fibrillation and flutter, aortic aneurysm, and endocarditis) among youths and young adults aged 15–39 years by age, sex, region, sociodemographic index and across 204 countries/territories from 1990 to 2019, and proportional DALY of CVDs attributable to associated risk factors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2019: a systematic analysis of Global Burden of Disease Study 2019
  2. 69322
    “…OBJECTIVE: The Triglyceride-glucose (TyG) index, a novel indicator of insulin resistance, has been associated with mortality from coronary artery diseases, ischemic stroke, and heart failure. In recent years, much emphasis has been placed on the relationship between the TyG index and mortality in the general population. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association of triglyceride glucose index with all-cause and cardiovascular mortality in the general population
  3. 69323
    por Sakata, Yasuhiko, Shiba, Nobuyuki, Takahashi, Jun, Miyata, Satoshi, Nochioka, Kotaro, Miura, Masanobu, Takada, Tsuyoshi, Saga, Chiharu, Shinozaki, Tsuyoshi, Sugi, Masafumi, Nakagawa, Makoto, Sekiguchi, Nobuyo, Komaru, Tatsuya, Kato, Atsushi, Fukuchi, Mitsumasa, Nozaki, Eiji, Hiramoto, Tetsuya, Inoue, Kanichi, Goto, Toshikazu, Ohe, Masatoshi, Tamaki, Kenji, Ibayashi, Setsuro, Ishide, Nobumasa, Maruyama, Yukio, Tsuji, Ichiro, Shimokawa, Hiroaki, Shimokawa, H., Fukuchi, M., Goto, T., Hiramoto, T., Inoue, K., Kato, A., Komaru, T., Ohe, M., Sekiguchi, N., Shiba, N., Shinozaki, T., Sugi, M., Tamaki, K., Hiramoto, T., Inoue, K., Kato, A., Ogata, M., Sato, S., Sugi, M., Ishide, N., Ibayashi, S., Maruyama, Y., Ohno, I., Tamaki, K., Ogawa, H., Kitakaze, M., Tsuji, I., Watanabe, T., Sugiyama, K., Oyama, S., Nozaki, E., Nakamura, A., Takahashi, T., Endo, H., Fukui, S., Nakajima, S., Nakagawa, M., Nozaki, T., Yagi, T., Horiguchi, S., Fushimi, E., Sugai, Y., Takeda, S., Fukahori, K., Aizawa, K., Ohe, M., Tashima, T., Sakurai, K., Kobayashi, T., Goto, T., Matsui, M., Tamada, Y., Yahagi, T., Fukui, A., Takahashi, K., Takahashi, K., Kikuchi, Y., Akai, K., Kanno, H., Kaneko, J., Suzuki, S., Takahashi, K., Akai, K., Katayose, D., Onodera, S., Hiramoto, T., Komatsu, S., Chida, M., Iwabuchi, K., Takeuchi, M., Yahagi, H., Takahashi, N., Otsuka, K., Koseki, Y., Morita, M., Shinozaki, T., Ishizuka, T., Onoue, N., Yamaguchi, N., Fujita, H., Katoh, A., Namiuchi, S., Sugie, T., Saji, K., Takii, T., Sugimura, A., Ohashi, J., Fukuchi, M., Ogata, M., Tanikawa, T., Kitamukai, O., Matsumoto, Y., Inoue, K., Koyama, J., Tomioka, T., Shioiri, H., Ito, Y., Kato, H., Takahashi, C., Kawana, A., Sakata, Y., Ito, K., Nakayama, M., Fukuda, K., Takahashi, J., Miyata, S., Sugimura, K., Sato, K., Matsumoto, Y., Nakano, M., Shiroto, T., Tsuburaya, R., Nochioka, K., Yamamoto, H., Aoki, T., Hao, K., Miura, M., Kondo, M., Tatebe, S., Yamamoto, S., Suzuki, H., Nishimiya, K., Yaoita, N., Sugi, M., Yamamoto, Y., Toda, S., Minatoya, Y., Takagi, Y., Hasebe, Y., Nihei, T., Hanawa, K., Fukuda, K., Sakata, Y., Takahashi, J., Miyata, S., Nochioka, K., Miura, M., Tadaki, S., Ushigome, R., Yamauchi, T., Sato, K., Tsuji, K., Onose, T., Abe, R., Saga, C., Suenaga, J., Yamada, Y., Kimura, J., Ogino, H., Oikawa, I., Watanabe, S., Saga, M., Washio, M., Nagasawa, K., Nagasawa, S., Kotaka, S., Komatsu, W., Hashimoto, R., Ikeno, Y., Suzuki, T., Hamada, H.
    Publicado 2015
    “…The primary endpoint was a composite of all-cause death, non-fatal acute myocardial infarction, non-fatal stroke, and hospitalization for worsening heart failure. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial
  4. 69324
    “…The change in end-diastolic and end-systolic volume equated to a 14 mL increase in stroke volume in the patients treated with 30 mg of pSDF-1 compared with a decrease of −11 mL in the placebo group (ΔSV = 25 mL, P = 0.09). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
  5. 69325
    “…It is important to identify whether mean group effects translate into clinically relevant increases for some individual patients, and/or increase the risk for serious cardiovascular adverse events such as stroke or sudden death. OBJECTIVES: To evaluate potential cardiovascular effects of these treatments, we conducted a systematic review and meta-analysis of the effects of methylphenidate (MPH), amphetamines (AMP), and atomoxetine (ATX) on diastolic and systolic blood pressure (DBP, SBP) and heart rate (HR) in children and adolescents with ADHD. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine
  6. 69326
    por Roth, Gregory A., Johnson, Catherine, Abajobir, Amanuel, Abd-Allah, Foad, Abera, Semaw Ferede, Abyu, Gebre, Ahmed, Muktar, Aksut, Baran, Alam, Tahiya, Alam, Khurshid, Alla, François, Alvis-Guzman, Nelson, Amrock, Stephen, Ansari, Hossein, Ärnlöv, Johan, Asayesh, Hamid, Atey, Tesfay Mehari, Avila-Burgos, Leticia, Awasthi, Ashish, Banerjee, Amitava, Barac, Aleksandra, Bärnighausen, Till, Barregard, Lars, Bedi, Neeraj, Belay Ketema, Ezra, Bennett, Derrick, Berhe, Gebremedhin, Bhutta, Zulfiqar, Bitew, Shimelash, Carapetis, Jonathan, Carrero, Juan Jesus, Malta, Deborah Carvalho, Castañeda-Orjuela, Carlos Andres, Castillo-Rivas, Jacqueline, Catalá-López, Ferrán, Choi, Jee-Young, Christensen, Hanne, Cirillo, Massimo, Cooper, Leslie, Criqui, Michael, Cundiff, David, Damasceno, Albertino, Dandona, Lalit, Dandona, Rakhi, Davletov, Kairat, Dharmaratne, Samath, Dorairaj, Prabhakaran, Dubey, Manisha, Ehrenkranz, Rebecca, El Sayed Zaki, Maysaa, Faraon, Emerito Jose A., Esteghamati, Alireza, Farid, Talha, Farvid, Maryam, Feigin, Valery, Ding, Eric L., Fowkes, Gerry, Gebrehiwot, Tsegaye, Gillum, Richard, Gold, Audra, Gona, Philimon, Gupta, Rajeev, Habtewold, Tesfa Dejenie, Hafezi-Nejad, Nima, Hailu, Tesfaye, Hailu, Gessessew Bugssa, Hankey, Graeme, Hassen, Hamid Yimam, Abate, Kalkidan Hassen, Havmoeller, Rasmus, Hay, Simon I., Horino, Masako, Hotez, Peter J., Jacobsen, Kathryn, James, Spencer, Javanbakht, Mehdi, Jeemon, Panniyammakal, John, Denny, Jonas, Jost, Kalkonde, Yogeshwar, Karimkhani, Chante, Kasaeian, Amir, Khader, Yousef, Khan, Abdur, Khang, Young-Ho, Khera, Sahil, Khoja, Abdullah T., Khubchandani, Jagdish, Kim, Daniel, Kolte, Dhaval, Kosen, Soewarta, Krohn, Kristopher J., Kumar, G. Anil, Kwan, Gene F., Lal, Dharmesh Kumar, Larsson, Anders, Linn, Shai, Lopez, Alan, Lotufo, Paulo A., El Razek, Hassan Magdy Abd, Malekzadeh, Reza, Mazidi, Mohsen, Meier, Toni, Meles, Kidanu Gebremariam, Mensah, George, Meretoja, Atte, Mezgebe, Haftay, Miller, Ted, Mirrakhimov, Erkin, Mohammed, Shafiu, Moran, Andrew E., Musa, Kamarul Imran, Narula, Jagat, Neal, Bruce, Ngalesoni, Frida, Nguyen, Grant, Obermeyer, Carla Makhlouf, Owolabi, Mayowa, Patton, George, Pedro, João, Qato, Dima, Qorbani, Mostafa, Rahimi, Kazem, Rai, Rajesh Kumar, Rawaf, Salman, Ribeiro, Antônio, Safiri, Saeid, Salomon, Joshua A., Santos, Itamar, Santric Milicevic, Milena, Sartorius, Benn, Schutte, Aletta, Sepanlou, Sadaf, Shaikh, Masood Ali, Shin, Min-Jeong, Shishehbor, Mehdi, Shore, Hirbo, Silva, Diego Augusto Santos, Sobngwi, Eugene, Stranges, Saverio, Swaminathan, Soumya, Tabarés-Seisdedos, Rafael, Tadele Atnafu, Niguse, Tesfay, Fisaha, Thakur, J.S., Thrift, Amanda, Topor-Madry, Roman, Truelsen, Thomas, Tyrovolas, Stefanos, Ukwaja, Kingsley Nnanna, Uthman, Olalekan, Vasankari, Tommi, Vlassov, Vasiliy, Vollset, Stein Emil, Wakayo, Tolassa, Watkins, David, Weintraub, Robert, Werdecker, Andrea, Westerman, Ronny, Wiysonge, Charles Shey, Wolfe, Charles, Workicho, Abdulhalik, Xu, Gelin, Yano, Yuichiro, Yip, Paul, Yonemoto, Naohiro, Younis, Mustafa, Yu, Chuanhua, Vos, Theo, Naghavi, Mohsen, Murray, Christopher
    Publicado 2017
    “…Ischemic heart disease was the leading cause of CVD health lost globally, as well as in each world region, followed by stroke. As SDI increased beyond 0.25, the highest CVD mortality shifted from women to men. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
  7. 69327
    “…Two composite primary outcome measures were evaluated: (i) CVD events/deaths (myocardial infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) serious adverse events (hypotension, syncope, electrolyte abnormalities, bradycardia, or acute kidney injury/failure). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials
  8. 69328
    Publicado 2019
    “…Similarly, the proportional reductions in stroke of any type (RR 0·84, 95% CI 0·80–0·89) did not differ significantly across age groups (p(trend)=0·7). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
  9. 69329
    “…The primary outcome was first occurrence of CV death, non-fatal myocardial infarction, or non-fatal stroke (3P-MACE), with an adjudicated secondary composite outcome of ESKD, renal death, or sustained ≥40% decrease in eGFR from baseline. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA
  10. 69330
    “…During further reduction of her steroid she was re-admitted 6 months later with new neurological symptoms in keeping with an acute stroke. Her MRI head demonstrated multiple infarcts possibly related either to vasculitis or embolic source. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    19. A case of giant cell arteritis (GCA) co-existent with systemic lupus erythematosus (SLE)/rheumatoid arthritis (RA) overlap syndrome
  11. 69331
    “…We expected to identify cases of acquired prosopagnosia, where the condition occurs only after brain damage, due to stroke, trauma, or meningitis for example, and cases of developmental prosopagnosia, where the condition is present from an early age, with no history of brain damage. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2093: Utilization of an ICD-coded electronic health records (EHR) database to characterize the epidemiology of prosopagnosia
  12. 69332
    “…DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 5 large, prospective, population-based cohorts of African American individuals in the Women’s Health Initiative (WHI) study, the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, the Multi-Ethnic Study of Atherosclerosis (MESA), the Jackson Heart Study (JHS), and the Atherosclerosis Risk in Communities (ARIC) study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals
  13. 69333
    “…In the interrupted time-series analysis, with the exception of acute alcohol-related events (0·98 [0·89–1·10]), there was evidence of a reduction in contacts for all conditions (anxiety 0·67 [0·66–0·67], eating disorders 0·62 [0·59–0·66], obsessive-compulsive disorder [0·69 [0·64–0·74]], self-harm 0·56 [0·54–0·58], severe mental illness 0·80 [0·78–0·83], stroke 0·59 [0·56–0·62], transient ischaemic attack 0·63 [0·58–0·67], heart failure 0·62 [0·60–0·64], myocardial infarction 0·72 [0·68–0·77], unstable angina 0·72 [0·60–0·87], venous thromboembolism 0·94 [0·90–0·99], and asthma exacerbation 0·88 [0·86–0·90]). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study
  14. 69334
    “…Compared with the COVID-19 neurology group, more patients in the PIMS-TS neurology group were admitted to intensive care (20 [80%] of 25 patients vs six [22%] of 27 patients, p=0·0001) and received immunomodulatory treatment (22 [88%] patients vs 12 [44%] patients, p=0·045). 17 (33%) patients (10 [37%] in the COVID-19 neurology group and 7 [28%] in the PIMS-TS neurology group) were discharged with disability; one (2%) died (who had stroke, in the PIMS-TS neurology group). INTERPRETATION: This study identified key differences between those with a primary neurological disorder versus those with PIMS-TS. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study
  15. 69335
    “…We included people aged 65 years or older, or 50 years or older with comorbidities (weakened immune system, heart disease, hypertension, asthma or lung disease, diabetes, mild hepatic impairment, stroke or neurological problem, and self-reported obesity or body-mass index of 35 kg/m(2) or greater), who had been unwell (for ≤14 days) with suspected COVID-19 or a positive PCR test for SARS-CoV-2 infection in the community. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
  16. 69336
    “…Venous thromboembolism (VTE), which encompasses both deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as arterial thromboembolism (ATE), which includes stroke, are common sequelae described in this patient population. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Impact of Treatment and Anticoagulation on Thrombosis in COVID-19 Patients
  17. 69337
    “…High levels of von Willebrand factor (VWF) and reduced levels of ADAMTS13 have been observed in COVID-19, sepsis, and immunothrombotic states, and an elevated VWF/ADAMTS13 ratio has been previously described in ischemic stroke(1). In this study, we sought to evaluate potential associations of VWF activity and antigen ratios to ADAMTS13 with clinical outcomes in hospitalized patients with COVID-19 and to compare these ratios with other cytokines and markers of inflammation in critical illness. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study
  18. 69338
    “…Incidence of thrombotic events (deep venous thrombosis, ischemic stroke, pulmonary embolism) was higher in cohort 1 (n=3, 4.8%) compared to cohort 2 (n=1, 2.6%). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients
  19. 69339
    “…Components of CHA (2)DS (2)-VASc, a model originally built for predicting ischemic stroke in atrial fibrillation, are consistent with independent risk factors for COVID-19 severity and mortality. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Risk Stratification for Acute Arterial and Venous Thromboembolism using CHA (2)DS (2)-VASc Score in Hospitalized COVID-19 Patients: A Multicenter Study
  20. 69340
    por Singh, Bhagteshwar, Lant, Suzannah, Cividini, Sofia, Cattrall, Jonathan W. S., Goodwin, Lynsey C., Benjamin, Laura, Michael, Benedict D., Khawaja, Ayaz, Matos, Aline de Moura Brasil, Alkeridy, Walid, Pilotto, Andrea, Lahiri, Durjoy, Rawlinson, Rebecca, Mhlanga, Sithembinkosi, Lopez, Evelyn C., Sargent, Brendan F., Somasundaran, Anushri, Tamborska, Arina, Webb, Glynn, Younas, Komal, Al Sami, Yaqub, Babu, Heavenna, Banks, Tristan, Cavallieri, Francesco, Cohen, Matthew, Davies, Emma, Dhar, Shalley, Fajardo Modol, Anna, Farooq, Hamzah, Harte, Jeffrey, Hey, Samuel, Joseph, Albert, Karthikappallil, Dileep, Kassahun, Daniel, Lipunga, Gareth, Mason, Rachel, Minton, Thomas, Mond, Gabrielle, Poxon, Joseph, Rabas, Sophie, Soothill, Germander, Zedde, Marialuisa, Yenkoyan, Konstantin, Brew, Bruce, Contini, Erika, Cysique, Lucette, Zhang, Xin, Maggi, Pietro, van Pesch, Vincent, Lechien, Jérome, Saussez, Sven, Heyse, Alex, Brito Ferreira, Maria Lúcia, Soares, Cristiane N., Elicer, Isabel, Eugenín-von Bernhardi, Laura, Ñancupil Reyes, Waleng, Yin, Rong, Azab, Mohammed A., Abd-Allah, Foad, Elkady, Ahmed, Escalard, Simon, Corvol, Jean-Christophe, Delorme, Cécile, Tattevin, Pierre, Bigaut, Kévin, Lorenz, Norbert, Hornuss, Daniel, Hosp, Jonas, Rieg, Siegbert, Wagner, Dirk, Knier, Benjamin, Lingor, Paul, Winkler, Andrea Sylvia, Sharifi-Razavi, Athena, Moein, Shima T., SeyedAlinaghi, SeyedAhmad, JamaliMoghadamSiahkali, Saeidreza, Morassi, Mauro, Padovani, Alessandro, Giunta, Marcello, Libri, Ilenia, Beretta, Simone, Ravaglia, Sabrina, Foschi, Matteo, Calabresi, Paolo, Primiano, Guido, Servidei, Serenella, Biagio Mercuri, Nicola, Liguori, Claudio, Pierantozzi, Mariangela, Sarmati, Loredana, Boso, Federica, Garazzino, Silvia, Mariotto, Sara, Patrick, Kimani N., Costache, Oana, Pincherle, Alexander, Klok, Frederikus A., Meza, Roger, Cabreira, Verónica, Valdoleiros, Sofia R., Oliveira, Vanessa, Kaimovsky, Igor, Guekht, Alla, Koh, Jasmine, Fernández Díaz, Eva, Barrios-López, José María, Guijarro-Castro, Cristina, Beltrán-Corbellini, Álvaro, Martínez-Poles, Javier, Diezma-Martín, Alba María, Morales-Casado, Maria Isabel, García García, Sergio, Breville, Gautier, Coen, Matteo, Uginet, Marjolaine, Bernard-Valnet, Raphaël, Du Pasquier, Renaud, Kaya, Yildiz, Abdelnour, Loay H., Rice, Claire, Morrison, Hamish, Defres, Sylviane, Huda, Saif, Enright, Noelle, Hassell, Jane, D’Anna, Lucio, Benger, Matthew, Sztriha, Laszlo, Raith, Eamon, Chinthapalli, Krishna, Nortley, Ross, Paterson, Ross, Chandratheva, Arvind, Werring, David J., Dervisevic, Samir, Harkness, Kirsty, Pinto, Ashwin, Jillella, Dinesh, Beach, Scott, Gunasekaran, Kulothungan, Rocha Ferreira Da Silva, Ivan, Nalleballe, Krishna, Santoro, Jonathan, Scullen, Tyler, Kahn, Lora, Kim, Carla Y., Thakur, Kiran T., Jain, Rajan, Umapathi, Thirugnanam, Nicholson, Timothy R., Sejvar, James J., Hodel, Eva Maria, Tudur Smith, Catrin, Solomon, Tom
    Publicado 2022
    “…The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis
Herramientas de búsqueda: RSS